BACKGROUND: The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active against several orthopoxviruses including vaccinia virus (VV), cowpox virus (CPV), camelpox virus (CMLV), ectromelia virus (ECTV) and variola virus in cell culture. The compound has been shown to inhibit the release of extracellular virus by targeting the F13L W protein and to protect mice from W, CPV and ECTV orthopoxvirus-induced disease. METHODS: The antiviral activity of ST-246 was assessed against extracellular and intracellular W, CPV and CMLV production in human embryonic lung (HEL) fibroblasts and primary human keratinocyte (PHK) cell monolayers, as well as in three-dimensional raft cultures. RESULTS: ST-246 inhibited preferentially the production of extracellular virus compared with intracellular virus production in HEL and PHK cells (for W) and in PHK cells (for CMLV). In organotypic epithelial raft cultures, ST-246 at 20 microg/ml inhibited extracellular W and CMLV production by 6 logs, whereas intracellular virus yield was reduced by 2 logs. In the case of CPV, both extracellular and intracellular virus production were completely inhibited by ST-246 at 20 microg/ml. Histological sections of the infected rafts, treated with increasing amounts of drug, confirmed the antiviral activity of ST-246: the epithelium was protected and there was no evidence of viral infection. Electron microscopic examination confirmed the absence of intracellular enveloped virus forms in W-, CPV- and CMLV-infected cells treated with 10 microg/ml of ST-246. CONCLUSIONS: These data indicate that ST-246 is a potent anti-orthopoxvirus compound; the mode of inhibition is dependent on the virus and cell type.
BACKGROUND: The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active against several orthopoxviruses including vaccinia virus (VV), cowpox virus (CPV), camelpox virus (CMLV), ectromelia virus (ECTV) and variola virus in cell culture. The compound has been shown to inhibit the release of extracellular virus by targeting the F13L W protein and to protect mice from W, CPV and ECTV orthopoxvirus-induced disease. METHODS: The antiviral activity of ST-246 was assessed against extracellular and intracellular W, CPV and CMLV production in human embryonic lung (HEL) fibroblasts and primary human keratinocyte (PHK) cell monolayers, as well as in three-dimensional raft cultures. RESULTS: ST-246 inhibited preferentially the production of extracellular virus compared with intracellular virus production in HEL and PHK cells (for W) and in PHK cells (for CMLV). In organotypic epithelial raft cultures, ST-246 at 20 microg/ml inhibited extracellular W and CMLV production by 6 logs, whereas intracellular virus yield was reduced by 2 logs. In the case of CPV, both extracellular and intracellular virus production were completely inhibited by ST-246 at 20 microg/ml. Histological sections of the infected rafts, treated with increasing amounts of drug, confirmed the antiviral activity of ST-246: the epithelium was protected and there was no evidence of viral infection. Electron microscopic examination confirmed the absence of intracellular enveloped virus forms in W-, CPV- and CMLV-infected cells treated with 10 microg/ml of ST-246. CONCLUSIONS: These data indicate that ST-246 is a potent anti-orthopoxvirus compound; the mode of inhibition is dependent on the virus and cell type.
Authors: Sophie Duraffour; Robert Drillien; Kazuhiro Haraguchi; Jan Balzarini; Dimitri Topalis; Joost J van den Oord; Graciela Andrei; Robert Snoeck Journal: Antimicrob Agents Chemother Date: 2013-10-14 Impact factor: 5.191
Authors: Mihai Ciustea; Janice Elaine Y Silverman; Abigail M Druck Shudofsky; Robert P Ricciardi Journal: J Med Chem Date: 2008-09-23 Impact factor: 7.446
Authors: Sophie Duraffour; Robert Snoeck; Marcela Krecmerová; Joost van Den Oord; Rita De Vos; Antonín Holy; Jean-Marc Crance; Daniel Garin; Erik De Clercq; Graciela Andrei Journal: Antimicrob Agents Chemother Date: 2007-09-24 Impact factor: 5.191
Authors: Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei Journal: J Virol Date: 2008-10-08 Impact factor: 5.103
Authors: Earl R Kern; Mark N Prichard; Debra C Quenelle; Kathy A Keith; Kamal N Tiwari; Joseph A Maddry; John A Secrist Journal: Antimicrob Agents Chemother Date: 2008-11-24 Impact factor: 5.191
Authors: Adams Amantana; Yali Chen; Shanthakumar R Tyavanagimatt; Kevin F Jones; Robert Jordan; Jarasvech Chinsangaram; Tove C Bolken; Janet M Leeds; Dennis E Hruby Journal: PLoS One Date: 2013-04-18 Impact factor: 3.752
Authors: Robert Jordan; Arthur Goff; Annie Frimm; Michael L Corrado; Lisa E Hensley; Chelsea M Byrd; Eric Mucker; Josh Shamblin; Tove' C Bolken; Carly Wlazlowski; Wendy Johnson; Jennifer Chapman; Nancy Twenhafel; Shanthakumar Tyavanagimatt; Adams Amantana; Jarasvech Chinsangaram; Dennis E Hruby; John Huggins Journal: Antimicrob Agents Chemother Date: 2009-02-17 Impact factor: 5.938